Literature DB >> 14509462

The effect of intravitreal triamcinolone acetonide on intraocular pressure.

Sophie J Bakri1, Paul M Beer.   

Abstract

BACKGROUND AND
OBJECTIVE: To ascertain whether a single 4-mg intravitreal triamcinolone acetonide injection is associated with elevated intraocular pressure (IOP). PATIENTS AND METHODS: Retrospective noncomparative interventional case series. Forty-three consecutive eyes of 38 patients who had 12 weeks of follow-up were included. The IOPs before and after triamcinolone acetonide treatment were recorded by Goldmann applanation at each patient visit.
RESULTS: Within 12 weeks after intravitreal triamcinolone acetonide injection, 21 of 43 eyes (48.8%) demonstrated an increase in IOP of 5 mm Hg or greater, and 12 of 43 eyes (27.9%) had an increase in IOP of 10 mm Hg or greater. The mean time for an increase in IOP of 5 mm Hg or greater to occur was 4.1 weeks (standard deviation = 4.8 weeks), and the mean time to reach maximum IOP was 6.6 weeks (standard deviation = 5.1). The difference between the mean pre-injection IOP (15.12 mm Hg, n = 43) and the maximum post-injection IOP (20.74 mm Hg, n = 43) was statistically significant (P < .0001).
CONCLUSION: A single 4-mg intravitreal triamcinolone acetonide injection is associated with an increase in IOP of 10 mm Hg or greater in 27.9% of eyes after the first injection. All eyes responded to topical glaucoma medication.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14509462

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  26 in total

Review 1.  [Ocular side effects and complications of intravitreal triamcinolone acetonide injection].

Authors:  G B Jaissle; P Szurman; K U Bartz-Schmidt
Journal:  Ophthalmologe       Date:  2004-02       Impact factor: 1.059

Review 2.  Management of sight-threatening uveitis: new therapeutic options.

Authors:  Matthias D Becker; Justine R Smith; Regina Max; Christoph Fiehn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behçet's disease.

Authors:  Leyla Suna Atmaca; F Nilüfer Yalçindağ; Ozden Ozdemir
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-01-17       Impact factor: 3.117

4.  Intravitreal anti-inflammatory treatment for uveitis.

Authors:  S Sugita
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

5.  Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye.

Authors:  B R Kosobucki; W R Freeman; L Cheng
Journal:  Br J Ophthalmol       Date:  2006-03-10       Impact factor: 4.638

6.  Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).

Authors:  Baruch D Kuppermann; Leandro Cabral Zacharias; M Cristina Kenney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

7.  Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections.

Authors:  A M Tammewar; L Cheng; O R Kayikcioglu; I A Falkenstein; I Kozak; M H Goldbaum; W R Freeman
Journal:  Br J Ophthalmol       Date:  2008-04-17       Impact factor: 4.638

8.  Intravitreal triamcinolone acetonide: Pattern of secondary intraocular pressure rise and possible risk factors.

Authors:  Ziad F Bashshur; Abdallah M Terro; Christelle P El Haibi; Akaber M Halawi; Alexandre Schakal; Baha' N Noureddin
Journal:  Clin Ophthalmol       Date:  2008-06

9.  Development of ocular hypertension and persistent glaucoma after intravitreal injection of triamcinolone.

Authors:  M Selim Kocabora; Cemil Yilmazli; Muhittin Taskapili; Gokhan Gulkilik; Sahan Durmaz
Journal:  Clin Ophthalmol       Date:  2008-03

10.  Intracameral dexamethasone reduces inflammation on the first postoperative day after cataract surgery in eyes with and without glaucoma.

Authors:  Diane T W Chang; Michael C Herceg; Richard A Bilonick; Larissa Camejo; Joel S Schuman; Robert J Noecker
Journal:  Clin Ophthalmol       Date:  2009-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.